Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by SkywalkerofLukeon Jan 16, 2023 5:03pm

167 Views

Post# 35226573

Recent News

After completing the Phase 2a study of Ifenprodil and seeing significant positive results, AGN.c AGNPF announced last week a 180 patient, 90-day Phase 2b clinical study of Ifenprodil for chronic cough to begin in Q3.

As Jacky Smith, Professor of Respiratory Medicine at the University of Manchester, stated, “I am very pleased Algernon has decided to conduct a stand-alone, Phase 2b study for cough . . . based on Algernon’s encouraging Phase 2a clinical data.”

The chronic cough market is expected to reach $11.38B by 2029 and with AGN planning to file an investigational new drug application with the FDA shortly, I’m watching AGN.

https://www.youtube.com/watch?v=REtP6b3LwY0

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages